Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 225

1.

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

Moses H Jr, Brandes DW.

Curr Med Res Opin. 2008 Sep;24(9):2679-90. doi: 10.1185/03007990802329959 .

PMID:
18694542
2.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
3.

Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.

Stuart WH.

Curr Med Res Opin. 2007 Jun;23(6):1199-208. Review.

PMID:
17559719
4.

A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events.

Brandes DW, Callender T, Lathi E, O'Leary S.

Curr Med Res Opin. 2009 Jan;25(1):77-92. doi: 10.1185/03007990802569455 . Review.

PMID:
19210141
5.

Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].

Smith B, Carson S, Fu R, McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A.

Portland (OR): Oregon Health & Science University; 2010 Aug.

6.

Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis.

Stuart WH, Cohan S, Richert JR, Achiron A.

Neurology. 2004 Dec 14;63(11 Suppl 5):S19-27. Review.

PMID:
15596732
7.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
8.

Considerations in the treatment of relapsing-remitting multiple sclerosis.

Calabresi PA.

Neurology. 2002 Apr 23;58(8 Suppl 4):S10-22. Review.

PMID:
11971122
9.

History of modern multiple sclerosis therapy.

Lublin F.

J Neurol. 2005 Sep;252 Suppl 3:iii3-iii9. Review.

PMID:
16170498
10.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
11.

Contemporary immunomodulatory therapy for multiple sclerosis.

Rudick RA.

J Neuroophthalmol. 2001 Dec;21(4):284-91. Review.

PMID:
11756861
12.
13.

Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.

Arnason BG.

J Neurol. 2005 Sep;252 Suppl 3:iii28-iii33. Review.

PMID:
16170497
14.

Current disease-modifying treatment of multiple sclerosis.

Derwenskus J.

Mt Sinai J Med. 2011 Mar-Apr;78(2):161-75. doi: 10.1002/msj.20239. Review.

PMID:
21425262
15.

Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.

Vartanian TK, Zamvil SS, Fox E, Sorensen PS.

Neurology. 2004 Dec 14;63(11 Suppl 5):S42-9. Review.

PMID:
15596736
16.

Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.

Sanford M, Lyseng-Williamson KA.

Drugs. 2011 Oct 1;71(14):1865-91. doi: 10.2165/11207540-000000000-00000. Review.

PMID:
21942977
17.

The importance of maintaining effective therapy in multiple sclerosis.

Durelli L, Clerico M.

J Neurol. 2005 Sep;252 Suppl 3:iii38-iii43. Review.

PMID:
16170500
18.

Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence.

Freedman SM.

Curr Med Res Opin. 2009 Mar;25(3):547-57. doi: 10.1185/03007990802677787 . Review.

PMID:
19232031
19.

Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment.

Bayas A, Gold R.

J Neurol. 2003 Dec;250 Suppl 4:IV3-8. Review.

PMID:
14712395
20.

[Drug therapy in multiple sclerosis].

Le Page E, Edan G.

Rev Prat. 2006 Jun 30;56(12):1336-46. Review. French.

PMID:
16948222
Items per page

Supplemental Content

Support Center